Document is current
Any future updates will be listed below
-
Authors
Machhi, Jatin
Yeapuri, Pravin
Lu, Yaman
Foster, Emma
Chikhale, Rupesh
Herskovitz, Jonathan
Namminga, Krista L.
Olson, Katherine E.
Abdelmoaty, Mai Mohamed
Gao, Ju
Quadros, Rolen M.
Kiyota, Tomomi
Jingjing, Liang
Kevadiya, Bhavesh D.
Wang, Xinglong
Liu, Yutong
Poluektova, Larisa Y.
Gurumurthy, Channabasavaiah B.
Mosley, R. Lee
Gendelman, Howard E. https://orcid.org/0000-0002-7831-0370
-
Funding
Funding for this research was provided by:
national institute on drug abuse (P01 DA028555)
national institute of neurological disorders and stroke (R01 NS36126, P01 NS31492, P01 NS43985, 2R01 NS034239)
national institute of mental health (P01 MH64570, P30 MH062261)
national institute on aging (R01 AG043540)
frances and louie blumkin and harriet singer research foundations
carol swarts, md emerging neuroscience research laboratory
margaret r. larson professorship
- License Information
-
More Information
Article History
Received: 2 July 2021
Accepted: 28 October 2021
First Online: 19 November 2021
Declarations
:
: All experiments using mice were carried out according to an Animal Use Protocol approved by the Institutional Animal Care and Use Committee at University of Nebraska Medical Center.
: All authors have approved the manuscript and agree with its submission.
: J.M., P.Y., B.D.K., C.B.G., R.L.M., and H.E.G. are named inventors on provisional patent entitled “Cells therapy for Alzheimer’s disease” which is based upon the Aβ-targeting T cells developed in the present study (EFS ID: 42475225, Application number: 63175747, Docket number: 21084P). H.E.G is a member of the scientific advisory board at Longevity Biotech and a co-founder of Exavir Therapeutics, Inc. All other authors declare no conflict of interest.
